In this first of two podcasts, 2 experts discuss risk factors and current recommendations for the diagnostic workup of ITP, and share strategies for initial management of newly diagnosed disease. Topics including corticosteroid overuse, approaches to improve remission rates, and contemporary concerns with COVID vaccination will be covered.. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.

Contributors:

Hanny Al-Samkari, MD
Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

Christopher Nelson, ACNP-BC, MBA
Nurse Practitioner
Hematology and Oncology
Avera Cancer Institute
Avera St Luke’s Hospital
Aberdeen, South Dakota

Dr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.

Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.